Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 4/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.34 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.34 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30560159 | 1.00 | DHODH (0.43) | DHODHPARP1PARP2PARP4CYP17A1 | |
| SCHEMBL28518923 | 0.96 | DHODH (0.41) | DHODHPARP1PARP2PARP4CYP17A1 | |
| SCHEMBL29598524 | 0.93 | DHODH (0.43) | DHODHCYP17A1CYP1A2TRPV1ELANE | |
| SCHEMBL465839 | 0.93 | DHODH (0.43) | DHODHCYP17A1CYP1A2TRPV1ELANE | |
| SCHEMBL12528168 | 0.93 | DHODH (0.43) | DHODHPARP1PARP4CYP17A1CYP1A2 | |
| SCHEMBL30466603 | 0.92 | DHODH (0.44) | DHODHPARP4CYP17A1CYP1A2TRPV1 | |
| SCHEMBL959396 | 0.92 | DHODH (0.44) | DHODHPARP4CYP17A1CYP1A2TRPV1 | |
| SCHEMBL31060018 | 0.91 | DHODH (0.37) | DHODHPARP1PARP2PARP4CYP17A1 | |
| SCHEMBL950948 | 0.90 | DHODH (0.39) | DHODHRAB9AMAPT | |
| SCHEMBL12528630 | 0.90 | DHODH (0.42) | DHODHCYP17A1CYP1A2KDM4ETRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3632911-B1 | METHOD FOR PREPARING ISOXAZINONE COMPOUND AND APPLICATION THEREOF | ZHEJIANG ZHUJI UNITED CHEMICALS CO LTD (CN) | 2023-08-09 | — | — | EP | disclosed |
| WO-2023079569-A1 | A PROCESS FOR PREPARING BENZOXAZINONE COMPOUNDS | TAGROS CHEMICALS INDIA PVT. LTD (IN) | 2023-05-11 | — | — | WO | disclosed |
| US-11299499-B2 | Preparation method and application of isoxazinone compounds | Zhejiang Zhuji United Chemicals Co., Ltd. (CN) | 2022-04-12 | — | — | US | disclosed |
| CN-110066270-B | Polyamide compound and preparation method and application thereof | 湖南化工研究院有限公司 | 2021-02-26 | — | — | CN | disclosed |
| CN-107033135-B | Method for preparing isooxazinone compound and application thereof | 浙江省诸暨合力化学对外贸易有限公司 | 2020-09-11 | — | — | CN | disclosed |
| US-20200109152-A1 | PREPARATION METHOD AND APPLICATION OF ISOXAZINONE COMPOUNDS | Zhejiang Zhuji United Chemicals Co., Ltd. (CN) | 2020-04-09 | — | — | US | disclosed |
| EP-3632911-A1 | METHOD FOR PREPARING ISOXAZINONE COMPOUND AND APPLICATION THEREOF | Zhejiang Zhuji United Chemicals Co., Ltd (CN) | 2020-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11299499-B2 | Preparation method and application of isoxazinone compounds | NISCH, SI, DAO | DHODH 240/4885PARP1 1954/4885PARP2 2167/4885 |
| US-20200109152-A1 | PREPARATION METHOD AND APPLICATION OF ISOXAZINONE COMPOUNDS | NISCH, SI, DAO | DHODH 240/4885PARP1 1954/4885PARP2 2167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.